Detalles de la búsqueda
1.
Safety and efficacy of tafasitamab with or without lenalidomide added to first-line R-CHOP for DLBCL: the phase 1b First-MIND study.
Blood
; 142(16): 1348-1358, 2023 10 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-37369099
2.
Treatment patterns and outcomes among nontransplant newly diagnosed multiple myeloma patients in Spain.
Future Oncol
; 17(26): 3465-3476, 2021 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-34342494
3.
High prognostic value of measurable residual disease detection by flow cytometry in chronic lymphocytic leukemia patients treated with front-line fludarabine, cyclophosphamide, and rituximab, followed by three years of rituximab maintenance.
Haematologica
; 104(11): 2249-2257, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30890600
4.
Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: The RETROGAH study.
J Geriatr Oncol
; 14(1): 101401, 2023 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-36404260
5.
Assessment of the psychometric properties of the Spanish version of EORTC QLQ-MY20 and evaluation of health-related quality of Life outcomes in patients with relapsed and/or refractory multiple myeloma in the real-world setting in Spain: results from the CharisMMa study.
Leuk Lymphoma
; 64(11): 1847-1856, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37539698
Resultados
1 -
5
de 5
1
Próxima >
>>